Abstract
The role of circulating proteins in Alzheimer’s disease and related dementias is unknown. Using a follow-up of two decades, 4953 plasma proteins, and discovery (Whitehall II) and replication cohort (ARIC), we examined plasma proteins associated with cognitive decline rate and dementia. After replication and adjustment for known dementia risk factors, fifteen proteins were associated with cognitive decline rate and dementia. None of these were amyloid, tau, or neurofilament-related proteins. Currently approved medications can target five of the proteins. The results support systemic pathogenesis of dementias, may aid in early diagnosis, and suggest potential targets for drug development.
Competing Interest Statement
In this is an academic industry partnership project academic collaborators generated the hypothesis and study design and SomaLogic, Inc. provided expertise in plasma proteins and funded SomaScan assays. SAW is employed by SomaLogic, Inc., which has a commercial interest in the results. ASM reports grants from the National Institute on Aging, NIH. RCL reports grants from Alzheimer's Research UK. RG was as previous Associate Editor for the journal Neurology. HZ reports grants from the Swedish Research Council, the European Research Council, Swedish State Support for Clinical Research, the Alzheimer Drug Discovery Foundation, USA, and the UK Dementia Research Institute. Additionally, HZ reports that he has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. EJB reports grants from British Heart Foundation and UK Research and Innovation. MK reports grants from UK Medical Research Council, US National Institute on Aging, Academy of Finland, Helsinki Institute of Life Science, NordForsk, and the Finnish Work Environment Fund, during the conduct of the study.
Funding Statement
The study was supported by the UK Medical Research Council (S011676, K013351, R024227), the National Institute on Aging (National Institutes of Health; R01AG056477 and R01AG062553), the British Heart Foundation (32334), the Academy of Finland (311492), NordForsk (75021), and SomaLogic, Inc. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from: Median gene-level TPM by tissue dataset from the GTEx Portal on 9/2/2020. JVL was supported by Academy of Finland (311492) and Helsinki Institute of Life Science (H970) and AS-M and AGT were supported by NordForsk (75021, the Nordic Research Programme on Health and Welfare), during the conduct of the study. ASM is supported by the National Institute on Aging, NIH (R01AG062553;R01AG056477). RCL was supported by Alzheimer's Research UK grant ARUK-NAS2017A-1. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (2018-02532), the European Research Council (681712), Swedish State Support for Clinical Research (ALFGBG-720931), the Alzheimer Drug Discovery Foundation, USA (201809-2016862), and the UK Dementia Research Institute at UCL. EJB was supported by British Heart Foundation (RG/16/11/32334) and UK Research and Innovation (ES/T014377/1). MK was supported by UK Medical Research Council (MR/S011676, MR/R024227), US National Institute on Aging (R01AG062553, R01AG056477), Academy of Finland (311492), Helsinki Institute of Life Science (H970), NordForsk (75021), and the Finnish Work Environment Fund (190424). The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I), R01HL087641, R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. Neurocognitive data is collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917 from the NIH (NHLBI, NINDS, NIA and NIDCD). Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. This study was also supported by contracts K23 AG064122 (Dr. Walker) and K24 AG052573 (Dr. Gottesman) from NIA. UCL and Johns Hopkins University have signed a collaboration agreement with SomaLogic, Inc to conduct SOMAscan of Whitehall and ARIC stored samples at no charge in exchange for the rights to analyse linked Whitehall and ARIC phenotype data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
At each examination, participants provided written informed consent for inclusion. Research ethics approval was granted by the University College London Hospital Committee on the Ethics of Human Research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data, protocols, and other metadata of the Whitehall II and ARIC studies are available to the scientific community. Please refer to the data sharing policies of these studies. Pre-existing data access policies for Whitehall II and ARIC studies specify that research data requests can be submitted to each steering committee; these will be promptly reviewed for confidentiality or intellectual property restrictions and will not unreasonably be refused. Individual-level patient or protein data may further be restricted by consent, confidentiality, or privacy laws/considerations. These policies apply to both clinical and proteomic data.
